Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.GSK, Prosensa treat first patient in DMD trial
GSK2402968, an antisense oligonucleotide which induces exon skipping of exon 51, is currently in late stage development for DMD. The study which is designed to evaluate the safety
GSK2402968, an antisense oligonucleotide which induces exon skipping of exon 51, is currently in late stage development for DMD. The study which is designed to evaluate the safety
In the preclinical studies Imetelstat have demonstrated activity against a range of cancer stem cells from both solid and hematological tumor types. In the trial, the patients will
The tie up will use Theraclone’s I-STAR technology for the discovery of protective monoclonal antibodies as a treatment for four undisclosed targets for infectious disease and cancer. As
Glenmark Pharma claims that its malaria drug is a generic version of GlaxoSmithKline (GSK’s) Malarone tablets, and will be marketed in strengths of 250mg and 100 mg. Glenmark
Cadence Pharma received the US Food and Drug Administration (FDA) approval for Ofirmev in November 2010 for the management of mild to moderate pain, the management of moderate
Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of Influenzavirus A and Influenzavirus B. Oseltamivir is an antiviral drug that slows the spread of influenza
ParaPRO claims that the lice medication is an easy-to-use product and it resolves head lice problems within 10 minutes with just one application. In two Phase III clinical
Pharmstandard is a Russian pharmaceutical company focused in R&D and production of the medicinal products. Pharmstandard operates three modern pharmaceutical manufacturing facilities: JSC Pharmstandard-Leksredstva in Kursk, JSC Pharmstandard-UfaVITA
Under a limited option-to-license agreement from Yeda, Prolor has been developing oxyntomodulin peptide, a drug compound using this technology as a treatment of obesity and has now exercised
On its part, to potentially help address the disease, the US-based Anavex is advancing ANAVEX 2-73, its lead drug candidate for Alzheimer’s disease. Reportedly, ANAVEX 2-73 is the